

APPLICANT (stamp or sticker acceptable) **PATIENT NHI:** **REFERRER** Reg No:

Reg No: First Names: First Names:

Name: Surname: Surname:

Address: DOB: Address:

..... Address:

.....

Fax Number: Fax Number:

Ibrutinib

Initial application — previously untreated chronic lymphocytic leukaemia in combination with venetoclax
Applications from any relevant practitioner. Approvals valid for 15 months.
Prerequisites(tick boxes where appropriate)

Individual is currently on treatment with ibrutinib and/or venetoclax and met all of the following criteria prior to commencing treatment

or

Individual has previously untreated CLL

and

Ibrutinib is to be administered at a maximum dose of 420 mg daily for 3 (28 day) cycles as monotherapy, followed by a maximum of 12 (28 day) cycles in combination with venetoclax

Initial application — chronic lymphocytic leukaemia (CLL)
Applications from any relevant practitioner. Approvals valid for 6 months.
Prerequisites(tick boxes where appropriate)

Individual has chronic lymphocytic leukaemia (CLL) requiring therapy

and

Ibrutinib is to be used as monotherapy

and

Individual has experienced intolerable side effects, or their disease has relapsed or is refractory following at least one prior line of therapy

and

Individual has not received ibrutinib monotherapy previously

Renewal — chronic lymphocytic leukaemia (CLL)
Current approval Number (if known):.....
Applications from any relevant practitioner. Approvals valid for 12 months.
Prerequisites(tick box where appropriate)

There is no evidence of disease progression

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL) and B-cell prolymphocytic leukaemia (B-PLL)*. Indications marked with * are Unapproved indications.

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz